Immuron Ltd (IMRN) is a well-established, globally recognized biopharmaceutical company that specializes in oral immunotherapy using polyclonal antibody products for the treatment and prevention of certain diseases and conditions. Founded in 1994, the company is headquartered in Melbourne, Australia but has since established a significant global presence.
Immuron primarily focuses on developing and commercializing treatments for infectious and inflammatory diseases. Its unique, patented polyclonal technology harnesses the power of the body's immune system to create targeted therapies with potential to treat various diseases that aren’t currently addressed adequately.
The company's most notable product is Travelan, an over-the-counter medicine designed to prevent travelers' diarrhea; however, the company also operates an impressive pipeline of potential treatments for fatty liver diseases, inflammatory bowel diseases, and other bacteria-induced diseases.
Immuron’s evident commitment to research and development has resulted in robust product development programs. Herein, the company's lead candidate, IMM-124E, has shown promising results in Phase II clinical trials for the treatment of NASH (Non-Alcoholic Steatohepatitis), an untreatable liver disease. Another product, IMM-529, is currently under development for clostridium difficile infections.
Immuron prides itself on its strategic collaborations and partnerships. It has boasted a long-term partnership with the U.S. Department of Defense to develop treatments for infectious diseases. The company has also collaborated with various academic institutions globally, including the U.S. Naval Medical Research Center, to conduct preclinical and clinical trials.
Immuron’s shares are traded on the Australian Securities Exchange (ASX) under the ticker symbol "IMC" and on the NASDAQ Capital Market in the United States under the ticker symbol "IMRN". The company continues to focus on driving shareholder value through the clinical development and commercialization of its product candidates.
Despite operating in a high-risk, high-reward industry, Immuron has consistently strived to advance its product pipeline through clinical trials and collaborations. The company's commitment to meeting unmet medical needs, significant scientific expertise, and strategic partnerships affirm its position as a key player in the biopharmaceutical industry. Immuron’s work pioneers the development of new treatments for multiple infectious and inflammatory diseases, contributing immensely to the global healthcare industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Immuron (NASDAQ:IMRN) reported unaudited global sales of AUD$2.2 million for fiscal first-quarter 2027, marking a 9% year-over-year increase. Australian sales saw a 14% rise to AUD$1.8 million, while U.S. sales declined by 19% to AUD$0.3 million due to inventory delays, and Canadian sales significantly increased to AUD$0.1 million. The company expects a positive outlook for the next quarter, citing replenished U.S. inventory and upcoming shopping events.
Immuron's travellers' diarrhoea tablet, Travelan, has surpassed Imodium in Australian pharmacy sales over the last 13 weeks, driven by a successful brand relaunch that boosted local sales by 14 percent in the September quarter. The company reported unaudited global sales of $2.2 million for Q1 FY27, with Australia contributing $1.8 million, while sales in the US declined and Canadian sales saw significant growth. Immuron expects improved US performance in the next quarter due to upcoming sales events and replenished inventory.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced double-digit sales growth for the quarter ending September 30, 2026, driven by a 14% increase in Australian Travelan® sales following a brand re-launch. Canadian Travelan® sales surged by 286% due to increased brand awareness, while US sales saw a 19% decrease but expect a positive outlook for the next quarter with upcoming Amazon Prime days and holiday sales events. The company also continues to expand market penetration for PROIBS® in Australia.
Biopharmaceutical company Immuron (ASX:IMC) reported $2.2 million in unaudited global sales for the quarter ended September 30, marking a 9% year-on-year and 5% quarter-on-quarter increase. Strong sales of Travelan in Australia and Canada drove this growth, effectively offsetting a 19% decline in the U.S. market. The company anticipates improved U.S. sales with replenished inventory ahead of major shopping events.
Immuron Limited has announced a reduction in the maximum aggregate offering price under its at-the-market (ATM) offering program with H.C. Wainwright & Co., LLC to $2,006,769. This revised limit excludes prior sales of $2,847,703 worth of securities within the last 12 months. The company filed a prospectus supplement and a legal opinion to reflect this change, with sales continuing under its existing Form F-3 shelf registration.